2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober B, Ferris L, Callis Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 90: 82-90. PMID: 37739267, DOI: 10.1016/j.jaad.2023.08.097.Peer-Reviewed Original ResearchDermatology Life Quality Index scoresLife Quality Index scoresPsoriasis RegistryQuality Index scoresSevere psoriasisPsoriasis symptomsClear skinIndex scoreReal-world treatment effectivenessPrior biologic treatmentSevere plaque psoriasisInflammatory skin diseasePatient-reported outcomesEntire study populationReal-world effectivenessSignificant reductionPlaque psoriasisEligible adultsPatient adherenceBiologic treatmentActivity impairmentObservational studyStudy populationRisankizumabPsoriasisAbrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study
Reich K, Silverberg J, Papp K, Deleuran M, Katoh N, Strober B, Beck L, de Bruin‐Weller M, Werfel T, Zhang F, Biswas P, DiBonaventura M, Chan G, Farooqui S, Kerkmann U, Clibborn C. Abrocitinib effect on patient‐reported outcomes in patients with moderate‐to‐severe atopic dermatitis: Results from phase 3 studies, including the long‐term extension JADE EXTEND study. Journal Of The European Academy Of Dermatology And Venereology 2023, 37: 2047-2055. PMID: 37319109, DOI: 10.1111/jdv.19254.Peer-Reviewed Original ResearchConceptsSevere atopic dermatitisPatient-reported outcomesAbrocitinib 200Phase 3 studyAtopic dermatitisWeek 48POEM scoresDermatology Life Quality Index scoresLong-term extension studyLife Quality Index scoresEczema Measure scoreManageable safety profilePatient-reported endpointsMean DLQI scorePatient-reported symptomsProportion of patientsPatient-reported responsesFull treatment periodPhase 3Quality Index scoresDLQI 0/1DLQI scoreWeek 12AD trialsSafety profileCharacteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study
Bunick C, Teng J, Guenthner S, Marathe K, Kempers S, Eads K, Castelo-Soccio L, Mendelsohn A, Raiz J, Murrell D. Characteristics and outcomes for participants with congenital ichthyosis who responded to treatment with the topical isotretinoin formulation TMB-001: results from the Phase IIb CONTROL study. Clinical And Experimental Dermatology 2023, 48: 765-769. PMID: 36928932, DOI: 10.1093/ced/llad105.Peer-Reviewed Original ResearchConceptsBSA involvementCongenital ichthyosisHigher DLQIIgA responsesTreatment successControl studyDermatology Life Quality Index scoresBody surface area involvementDose-limiting adverse effectGlobal assessmentLife Quality Index scoresInvestigator's Global AssessmentSurface area involvementProportion of participantsRating Scale scoresSystemic retinoid treatmentYears of ageQuality Index scoresCharacteristics of participantsIgA respondersBaseline demographicsEfficacy endpointMedian ageArea involvementScale score
2022
Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Goldburg S, Chen R, Langholff W, Lafferty K, Gooderham M, de Jong E, Strober B. Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 132-139. PMID: 39296535, PMCID: PMC11361528, DOI: 10.1177/24755303221099848.Peer-Reviewed Original ResearchPsoriasis Longitudinal AssessmentDisease characteristicsDermatology Life Quality Index scoresDisease severitySystemic therapy-naïve patientsLife Quality Index scoresLongitudinal assessmentPhysician global assessmentSystemic steroid therapyLifestyle risk factorsTherapy-naïve patientsNonmelanoma skin cancerObjective disease severityBody surface areaHistory of anxietyQuality Index scoresQuality of lifeChi-square testPsoriasis characteristicsSteroid therapySevere psoriasisTherapy-naïveDisease durationBiologic-naïvePatient characteristics
2020
0855 Primary Sleep Disorders And The Combined Outcome Of Poor Sleep Quality With Objective Short Sleep Duration In Older Persons
Miner B, Fragoso C, Han L, Stone K, Redeker N, Yaggi H. 0855 Primary Sleep Disorders And The Combined Outcome Of Poor Sleep Quality With Objective Short Sleep Duration In Older Persons. Sleep 2020, 43: a325-a326. DOI: 10.1093/sleep/zsaa056.851.Peer-Reviewed Original ResearchPrimary sleep disordersShort sleep durationPoor sleep qualityHigh-risk phenotypeSleep disordersSleep qualityOlder personsOsteoporotic fracturesMultivariable modelUnadjusted modelsSleep durationClaude D. Pepper Older Americans Independence CenterCombined outcomeObjective short sleep durationPittsburgh Sleep Quality Index scoreSelf-reported chronic conditionsMultivariate logistic regression modelAverage total sleep timeMen Sleep StudyCross-sectional associationsTotal sleep timeQuality Index scoresLogistic regression modelsMedication usePsychiatric comorbidity
2018
Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials. British Journal Of Dermatology 2018, 180: 67-75. PMID: 30188571, PMCID: PMC7379291, DOI: 10.1111/bjd.17149.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAgedAged, 80 and overChronic DiseaseDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesQuality of LifeRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexYoung AdultConceptsSevere chronic plaque psoriasisChronic plaque psoriasisEfficacy end pointBenefit-risk profileSevere psoriasisPlaque psoriasisWeek 16Dermatology Life Quality Index scoresLong-term extension studyOral Janus kinase inhibitorGlobal assessmentLife Quality Index scoresEnd pointDepression Scale depression scorePhysician global assessmentImproved patients' qualitySystemic psoriasis therapiesJanus kinase inhibitorQuality Index scoresTofacitinib 5Tofacitinib exposurePsoriasis AreaSystemic treatmentTofacitinib treatmentPatients' qualityEffects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS)
Cintron D, Lahr BD, Bailey KR, Santoro N, Lloyd R, Manson JE, Neal-Perry G, Pal L, Taylor HS, Wharton W, Naftolin F, Harman SM, Miller VM. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). Menopause The Journal Of The North American Menopause Society 2018, 25: 145-153. PMID: 28832429, PMCID: PMC5771895, DOI: 10.1097/gme.0000000000000971.Peer-Reviewed Original ResearchConceptsKronos Early Estrogen Prevention StudyHormone therapyDomains of sleepSleep qualityDomain scoresMenopausal womenPrevention StudySleep domainsGlobal Pittsburgh Sleep Quality Index scoreOral conjugated equine estrogenPittsburgh Sleep Quality Index scorePittsburgh Sleep Quality IndexVasomotor symptom scoresConjugated equine estrogensSleep Quality IndexPoor sleep qualityGlobal sleep qualitySeverity of symptomsGlobal sleep scoreQuality Index scoresMenopausal hormonesVMS severityPostmenopausal womenVasomotor symptomsSpearman correlation coefficient
2017
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Journal Of Drugs In Dermatology 2017, 16: 801-808. PMID: 28809995.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisSafety of apremilastPlaque psoriasisGlobal assessment scoreStatic Physician's Global Assessment scoreDermatology Life Quality Index scoresUpper respiratory tract infectionPhysician Global Assessment scoreLife Quality Index scoresPercentage changePrior topical therapyMost adverse eventsPrimary efficacy endpointSevere plaque psoriasisTreatment Satisfaction QuestionnaireRespiratory tract infectionsHigh patient satisfactionMean percentage changeQuality Index scoresQuality of lifeGreater percentage changeEfficacy endpointAdverse eventsTopical therapyTract infections
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply